PCRS advocates that: 

In this article the authors review current evidence and guidance for the treatment of Chronic obstructive pulmonary disease (COPD) to bring up to date the Primary Care Respiratory Society (PCRS) consensus approach and algorithm first published in 2017 and then again in 2023 known as ‘Keeping it Simple’.

Winter brings predictable surges in respiratory illness and pressure across urgent and emergency care. This paper sets out a practical, primary care-led framework to reduce avoidable demand by acting earlier on respiratory risk. We describe seven interventions:

The autumn/winter edition of your members’ magazine packed with useful features, clinical updates, educational updates, respiratory news and opinion.

This summary infographic provides an overview of the new MART therapy which has been licensed for children of 6 - 11 years old. It provides a breakdown of what the new licensed product is, who it is appropriate for, when to consider introducing your asthma patients to it and how it should be implemented to ensure it is introduced effectively. Acknowledgement

PCRS held a webinar on Implementing AIR and MART in children (6+), young people and adults. With new licenses coming in quickly for AIR and MART inhaler treatments, it is important to implement them effectively, in the appropriate age grounds.In this webinar, Chair Katherine Hickman (PCRS Executive Chair) and guest speakers Deborah Leese and Lisa Cummings focus on:

The BTS/NICE/SIGN asthma guidelines now recommend moving away from blue (reliever) and brown (preventer) inhalers. Many people with asthma still rely on their blue inhaler despite the fact they:Do not treat the underlying inflammation, andCan result in worse asthma control and increased symptoms. Brown inhalers also often do not treat the symptoms quick enough. 

Anti-inflammatory reliever (AIR) is a single inhaler treatment for asthma which can be used by people with asthma and who experience asthma symptoms twice a week or less. It removes the need to have separate preventer (brown) and reliever (blue) inhalers.